سعر ستراتيرا 40 مجم 28 كبسولة 2026

Atomoxetine 40 mg oral capsules, pack of 28 (Eli Lilly); selective norepinephrine reuptake inhibitor for ADHD.

• Treatment of ADHD in adults and pediatric patients 6 years and older, as part of a total treatment program.Population: Adults and children 6 years and olderDailyMed (NLM)

• Most common in pediatric studies: nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence.International label, same formulation · DailyMed (NLM)
• Most common in adult studies: constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, urinary hesitation.International label, same formulation · DailyMed (NLM)

• Hypersensitivity to atomoxetine or other constituents (including anaphylaxis, angioedema).International label, same formulation · DailyMed (NLM)
• Use with, or within 14 days of stopping, an MAOI.International label, same formulation · DailyMed (NLM)
• Narrow angle glaucoma.International label, same formulation · DailyMed (NLM)

• Boxed warning: increased risk of suicidal thoughts and behaviors in pediatric patients 6 years and older; monitor closely, especially early in therapy and at dose changes.International label, same formulation · DailyMed (NLM)
• Severe liver injury: discontinue and do not restart in patients with jaundice or laboratory evidence of liver injury.International label, same formulation · DailyMed (NLM)
• Serious cardiovascular reactions: assess for cardiovascular disease before treatment; measure heart rate and blood pressure at baseline and periodically.International label, same formulation · DailyMed (NLM)

• MAOIsContraindicated together or within 14 days.DailyMed (NLM)
• Strong CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine)Increase atomoxetine exposure; dose adjustment/slower titration recommended.DailyMed (NLM)
• Antihypertensive and pressor agentsPossible effects on blood pressure; monitor.DailyMed (NLM)

• Available published data in pregnant women are insufficient to establish a drug-associated risk; some animal studies showed adverse developmental outcomes; a pregnancy exposure registry exists.International label, same formulation · DailyMed (NLM)
• No data on presence in human milk; present in animal milk; weigh benefits of breastfeeding against maternal need and potential infant risk.International label, same formulation · DailyMed (NLM)

• Atomoxetine: Thought to act through selective inhibition of the presynaptic norepinephrine transporter; precise mechanism in ADHD unknown (US label).